Listing of Claims

Claims 1-8. (Cancelled)

Claim 9. **(Cancelled)**

Claim 10. (Currently amended) **[[The]]** A composition ~~**of Claim 9**~~ **comprising a therapeutically-effective amount of a cyclooxygenase-2 selective inhibitor, a 5-lipoxygenase selective inhibitor and an immunosuppressive drug selected from antiproliferation agents, antiinflammatory-acting compounds and inhibitors of leukocyte activation** wherein the cyclooxygenase-2 **selective** inhibitor is selected from 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-thiophene, N-[2-cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide, 1,1-dioxide-4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide, N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]-methanesulfonamide and compounds of Formula I or a pharmaceutically acceptable salt of a compound having Formula I:



(I)

wherein A is a 5-or 6-member ring substituent selected from partially unsaturated or unsaturated heterocyclo and carbocyclic rings;

wherein R^1 is at least one substituent selected from heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R^1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl,

hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R^2 is selected from alkyl, and amino; and

wherein R^3 is a radical selected from halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclooxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N–arylaminosulfonyl, arylsulfonyl, **and** N-alkyl-N-arylaminosulfonyl.

Claim 11. (Currently amended) The composition of Claim **[[9]]** **10** wherein the 5-lipoxygenase **selective** inhibitor is selected from (R*,S*)-4,4-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol, (Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide, N-(1-Benzo[b]thien-2-yl-ethyl)-N-hydroxyurea, 4-[2',4'-difluorbiphenyl]-4-oxo-methyl-butanic acid, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridinyl)-2-propenamide, 1-methyl-6-[[[3-(tetrahydro-4-methoxy-2-methyl-2H-pyran-4-yl)-2-propenyl]oxy]methyl]-2(1H)-quinolinone, N-Hydroxy-N-[4-[3-(4-fluorophenoxy)phenyl]-3-butyn-2-yl]-urea, N-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N-hydroxyurea, N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propynyl]-N-hydroxyurea, (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-

propynyl]-N-hydroxyurea, N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridyl) acrylamide, (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl-acetic acid, dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one, 2-butyl-4-methoxy-1-naphthalenol-acetate, N'-[[2-[2-[(4-chlorophenyl)thio] ethoxy]-3-methoxy-5-[(2R,5R)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl] phenyl]methyl]-N-hydroxy-N-methyl-urea, 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone, 4,6-dimethyl-2-[(6-phenyl hexyl)amino]-5-pyrimidinol phosphate (1:1) (salt), 4-(2-quinolylmethoxy)-N-(3-fluorobenzyl-phenyl-amino-methyl-4-benzoic-acid, 4-[(4-fluorophenyl) methyl]-2-[hexahydro-1-(2-phenylethyl)-1H-azepin-4-yl]-1(2H)-phthalazinone, 3-[1-(4-chlorobenzyl)-3-*t*-butyl-thio-5-isopropylindol-2-yl]-2, 2-dimethylpropanoic acid,[2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid, 6-[[4-(4-chlorophenoxy) phenoxy]methyl]-1-hydroxy-4-methyl-2(1H)-pyridinone, 10-(3-chlorophenyl)-6,8,9,10-tetrahydro-benzo[b][1,8]naphthyridin-5(7H)-one, 5-(4-chlorophenyl)-N-hydroxy-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide, 1-([5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]aminoethyl)-4-diphenylmethoxypiperidine, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone, 2-amino-5-hydroxy-8-methylnonyl ester-benzoic acid, 3,6-dimethoxy-1,2-dimethyl-9H-carbazol-4-ol, 6-diazo-3-methyl-4-[(1E)-1,3,5-trimethyl-1-hexenyl]-2,5,7,8(1H,6H)-quinolinetetrone, N-[2-[[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-1,2,3,4-tetrahydro-1-oxo-6-isoquinolinyl]oxy]ethyl]-N-hydroxy-urea, (Z)-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-methylene]-2-imino-4-thiazolidinone- methanesulfonate salt, 4-[4,6-bis-t-butyl-5-hydroxy-2-pyrimidinyl]-1,3-dihydro-5-methyl-2H-imidazol-2-one, 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)-benzothiazole, N-[2-(4-(benzhydryloxy)piperidino)ethyl]-3-hydroxy-5-(3-pyridylmethoxy)-2-naphthamide, 2,2-dibutyl-1,2,3,4-tetrahydro-5-(2-quinolinylmethoxy)-1-naphthalenol, (2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]-butanoic acid, 1,6-anhydro-3-C-[6-[[[7-cyano-5-(3-

furanyl)-2-naphthal enyl]oxy]methyl]-2-pyridinyl]-2,4-dideoxy-*b*-D-threo-hexopyranose, 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxy phenyl]methylene]-3-(methylamino)-4-thiazolidinone, 5-[[3,5-bis(1,1-dimethyl ethyl)-4-hydroxyphenyl]methylene]-4-thiazolidinone, (S)-N-hydroxy-N-(2,3-dihydro-6-phenylmethoxy-3-benzyofuranyl)-urea, 1-[(4-chlorophenyl)methyl]-2-methyl-5-(2-quinolinylmethoxy)-1H-indole-3-acetic acid, 2-[2,3-dihydro-1-methoxy-6-(2-naphthalenylmethoxy)-1H-inden-1-yl]-thiazole, (6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxymethyl]-1-ethyl-2-quinolone, 1,2-dihydro-n-(2-thiazolyl)-1-oxopyrrolo(3,2,1-kl)phenothiazine-1-carboxamide, tetrahydro-1-phenyl-1,2,4-triazin-3(2H)-one, N-[1-(3-Furyl)ethyl]-N-hydroxyurea, N-hydroxy-N-[1-[4-(phenylmethoxy)phenyl]ethyl]-acetamide, 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]-3-methoxyphenyl]-ethanone, mono[2,6-dimethyl-4-[(1E)-2-(2-thienyl) ethenyl]phenyl]-butanedioic acid, 2,6-bis(1,1-dimethylethyl)-4-[2-(3-pyridinyl)ethenyl]-phenol, 2,6-dimethyl-4-[2-(2-thienyl)ethenyl]-phenol, 9-phenylnonanophydroxamic acid, 4-hydroxy-3-methoxy-1,2-dimethylcarbazole, N-hydroxy-N-[1-methyl-3-(3-phenoxyphenyl)-2-propenyl]-acetamide, 2-phenylhydrazide-benzenecarboximidic acid, 4-(cyclohexyl methylamino)-1,2-naphthalenediol, diacetate ester, (2E)-3-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]-N-hydroxy-N-methyl-2-propenamide, N-hydroxy-N-[(6-phenoxy-2H-1-benzopyran-3-yl)methyl]-urea, N-[[6-(4-fluorophenoxy)-2H-1-benzopyran-3-yl]methyl]-N-hydroxy-N-methyl-urea, methyl 2-[(3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino]-benzoate, monohydrobromide-6-(2,2-dimethylhydrazino)-5,6,7,8-tetrahydro-1,2-naphthalenediol, 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt, 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2,4-thiazolidinedione, 3',4',5-trihydroxy-6,7-dimethoxyflavone, 3,5,6-trimethyl-1,4-dione- 2-(12-hydroxy-5,10-dodecadiynyl)-2,5-cyclohexadiene, 2-benzyl-1-naphthol, N-methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene pyrrolidin-2-one, 6-hydroxy-2-(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazole hydrochloride, 4-[(1E)-2-(4-fluorophenyl)ethenyl]-2,6-dimethyl-phenol, 1,6-diol, 4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylbutyl) oxiranyl]-9H-

carbazole, 5-(3-phenylpropyl)-2-thiophenepentanoic acid, 4,5-dihydro-5-methyl-1-(4,5,6,7-tetrahydro-2-benzothiazolyl)-1H-pyrazol-3-amine, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]-2-(3,4-dihydroxy phenyl)ethyl-6-O-(6-deoxy-a-L-mannopyranosyl)-β-D-Glucopyranoside, N-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine, 1-[3-(naphth-2-ylmethoxy)phenyl]-1-(thiazol-2-yl)propyl methyl ether, 2-N-heptyl-4-hydroxyquinoline-N-oxide, 4-bromo-2,7-dimethoxy-3,4-phenothizin-3-one, 6-[1-[2-(hydroxymethyl)phenyl]-1-propen-3-yl]-2,3-dihydro-5-benzofuranol, 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo(b)thiophene-2-carboxamide, 2-[(4-methoxyphenyl)methyl]-3-methyl-4-hydroxy-5-propyl-7-chlorobenzofuran, 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol, [[4-(4-chlorophenyl)-1-[4-(2-quinolinylmethoxy)phenyl]butyl] thio]-acetic acid, N-hydroxy-N-methyl-3-[2-(methylthio)phenyl]-2-propenamide, 3-(1((4-chlorophenyl)methyl)-3((1,1-dimethyl-ethyl)thio)-5(quinolin-2-yl-methyl-oxy)-1H-indol-2-yl)-2,2-dimethyl-propanoate, N-hydroxy-14-methyl-N-nitroso-1-pentadecanamine, 2-amino-4-[(4-methylphenyl)thio]-phenol hydrochloride, (2E,11Z,14Z)-N-[2,3-dihydro-3-(1H-tetrazol-5-yl)-1,4-benzodioxin-5-yl]-N-methyl-2,11,14-eicosatrienamide, (2E,11Z,14Z)-N-[4-hydroxy-2-(1H-tetrazol-5-yl)-8-quinolinyl]-2,11,14-eicosatrienamide, (E)-2,6-bis(1,1-dimethyl-ethyl)-4-[2-(5-methyl-1H-pyrazol-3-yl)ethenyl]-phenol, 2-[3(1-hydroxyhexyl)phenoxymethyl]-quinoline hydrochloride, N-hydroxy-N-methyl-7-propoxy-2-naphthaleneethanamine, methyl-2-[[3-(1-hydroxypentyl) phenoxy]methyl]-benzoic acid (ester), a-pentyl-3-(2-quinolinylmethoxy)-benzenemethanol, N–hydroxy-N-methyl-4-(phenylmethoxy)-benzeneacetamide, 3-(3,5-bis(1,1-dimethyl)-4-hydroxyphenyl)thiol]-N-methyl-N-[2-(2-pyridinyl-propanamide), (R*, S*)-1-methylpropoxy]-[(1R,2S)-2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-acetic acid, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-5H-pyrrolo[1,2-a]-imidazole, 6,7-dihydro-2-(4-methoxyphenyl)-3-(4-pyridinyl)-5H-pyrrolo[1,2-a]-imidazole, 2-(4-methylsulfinylphenyl)-3-(4-pyridyl)-6,7-dihydro-[5H]-pyrrolo[1,2-a]-imidazole, (7E)-8-(2-naphthyl)-5,6-trans-5,6-methano-7-octenoic acid, (2E,4E)-N-[2-[4-(diphenyl methoxy)-1-piperidinyl] ethyl]-5-(4-hydroxy-3-methoxyphenyl)-

2,4-pentadienamide, (2E)-N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-(4-hydroxy-3-methoxy phenyl)-2-propenamide, (2E)-N-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-3-(4-hydroxy-3-methoxy phenyl)-2-propenamide, (2Z,5Z,8Z,11Z,14Z,17Z)-N-[4-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]amino]butyl]-2,5,8,11,14,17-eicosahexaenamide, (2E)-N-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl]ethyl]-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide, 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-3-methylindole, 1,8-diethyl-1,3,4,9-tetrahydro-6-(2-quinolinylmethoxy)-pyrano[3,4-b]indole-1-acetic acid, 2-[(1-naphthalenyloxy)methyl]-quinoline, 1,1,1-trifluoro-N-[3-(2-quinolinylmethoxy)phenyl]-methanesulfonamide, α-methyl-6-(2-quinolinylmethoxy)-2-naphthalene-acetic acid, and 1-butyl-5-hydroxy-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-1H-indole-3-carboxamide, hydrochloride.

Claim 12. (Currently amended) The composition of Claim 11 wherein the 5-lipoxygenase **selective** inhibitor is selected from (R*,S*)-4,4-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol, (Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide, N-(1-Benzo[b]thien-2-yl-ethyl)-N-hydroxyurea, 4-[2',4'-difluorbiphenyl]-4-oxo-methyl-butanic acid, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridinyl)-2-propenamide, 1-methyl-6-[[[3-(tetrahydro-4-methoxy-2-methyl-2H-pyran-4-yl)-2-propenyl]oxy]methyl]-2(1H)-quinolinone, N-Hydroxy-N-[4-[3-(4-fluorophenoxy)phenyl]-3-butyn-2-yl]-urea, N-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N-hydroxyurea, N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propynyl]-N-hydroxyurea, (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea, N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridyl) acrylamide, (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl-acetic acid, dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one, 2-butyl-4-methoxy-1-naphthalenol-acetate, N'-[[2-[2-[(4-chlorophenyl)thio] ethoxy]-3-methoxy-5-[(2R,5R)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl] phenyl]methyl]-N-

hydroxy-N-methyl-urea, 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone, N-[2-[[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-1,2,3,4-tetrahydro-1-oxo-6-isoquinolinyl]oxy]ethyl]-N-hydroxy-urea, 4,6-dimethyl-2-[(6-phenyl hexyl)amino]-5-pyrimidinol phosphate (1:1) (salt), 4-(2-quinolylmethoxy)-N-(3-fluorobenzyl-phenyl-amino-methyl-4-benzoic-acid, 4-[(4-fluorophenyl) methyl]-2-[hexahydro-1-(2-phenylethyl)-1H-azepin-4-yl]-1(2H)-phthalazinone, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, 3-[1-(4-chlorobenzyl)-3-*t*-butyl-thio-5-isopropylindol-2-yl]-2, 2-dimethylpropanoic acid, (2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]-butanoic acid, [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid, 6-[[4-(4-chlorophenoxy) phenoxy]methyl]-1-hydroxy-4-methyl-2(1H)-pyridinone, 10-(3-chlorophenyl)-6,8,9,10-tetrahydro- benzo[b][1,8]naphthyridin-5(7H)-one, 5-(4-chlorophenyl)-N-hydroxy-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide, 1-([5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]aminoethyl)-4-diphenylmethoxypiperidine, 2-[2,3-dihydro-1-methoxy-6-(2-naphthalenylmethoxy)-1H-inden-1-yl]-thiazole, (6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxymethyl]-1-ethyl-2-quinolone, and 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone.

Claim 13. (Currently amended) The composition of Claim 12 wherein the 5-lipoxygenase **selective** inhibitor is selected from (Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide, N-(1-Benzo[b]thien-2-yl-ethyl)-N-hydroxyurea, 4-[2',4'-difluorbiphenyl]-4-oxo-methyl-butanic acid, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridinyl)-2-propenamide, 1-methyl-6-[[[3-(tetrahydro-4-methoxy-2-methyl-2H-pyran-4-yl)-2-propenyl]oxy]methyl]-2(1H)-quinolinone, N-Hydroxy-N-[4-[3-(4-fluorophenoxy)phenyl]-3-butyn-2-yl]-urea, N-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N-hydroxyurea, N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-

propynyl]-N-hydroxyurea, (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea, N-[2-[[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-1,2,3,4-tetrahydro-1-oxo-6-isoquinolinyl]oxy]ethyl]-N-hydroxy-urea, dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one, 4-(2-quinolylmethoxy)-N-(3-fluorobenzyl-phenyl-amino-methyl-4-benzoic-acid, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]-butanoic acid, [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid, 1-([5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]aminoethyl)-4-diphenylmethoxypiperidine, 2-[2,3-dihydro-1-methoxy-6-(2-naphthalenylmethoxy)-1H-inden-1-yl]-thiazole, (6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxymethyl]-1-ethyl-2-quinolone, and 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone.

Claim 14. (Previously presented) The composition of claim 10 wherein A is selected from oxazolyl, isoxazolyl, thienyl, dihydrofuryl, furyl, pyrrolyl, pyrazolyl, thiazolyl, imidazolyl, isothiazolyl, cyclopentenyl, phenyl, and pyridyl; wherein R^1 is selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R^1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio; wherein R^2 is selected from lower alkyl and amino; and wherein R^3 is a radical selected from halo, lower alkyl, oxo, cyano, carboxyl, lower cycloalkyl, heteroaryloxy, lower alkyloxy, lower cycloalkyl, phenyl, lower haloalkyl, 5- or 6-membered heterocyclo, lower hydroxyalkyl, lower aralkyl, acyl, phenylcarbonyl, lower alkoxyalkyl, heteroaryloxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylamino, aminoalkyl, alkylaminoalkyl, aryloxy, and aralkoxy.

Claim 15. (Previously presented) The composition of Claim 14 wherein A is selected from oxazolyl, isoxazolyl, dihydrofuryl, imidazolyl, and pyrazolyl; wherein R^1 is selected from 5- and 6-membered heterocyclo, and aryl selected from phenyl, biphenyl and naphthyl, wherein R^1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio; wherein R^2 is amino; and wherein R^3 is a radical selected from oxo, cyano, carboxyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, halo, lower alkyl, lower alkyloxy, lower cycloalkyl, phenyl, lower haloalkyl, 5- or 6-membered heterocyclo, lower hydroxyalkyl, lower aralkyl, acyl, phenylcarbonyl, lower alkoxyalkyl, 5- or 6-membered heteroaryloxy, aminocarbonyl, lower alkylaminocarbonyl, lower alkylamino, lower aminoalkyl, lower alkylaminoalkyl, phenyloxy, and lower aralkoxy.

Claim 16. (Previously presented) The composition of Claim 15 wherein A is selected from oxazolyl, isoxazolyl, imidazolyl, and pyrazolyl; wherein R^1 is phenyl optionally substituted at a substitutable position with one or more radicals selected from methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, trifluoromethyl, cyano, carboxyl, methoxycarbonyl, hydroxyl, hydroxymethyl, trifluoromethoxy, amino, N-methylamino, N,N-dimethylamino, N-ethylamino, N-dipropylamino, butylamino, methyl-N-ethylamino, nitro, methoxymethyl, methylsulfinyl, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, and methylthio; wherein R^2 is amino; and wherein R^3 is a radical selected from oxo, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, carboxypropyl, carboxymethyl, carboxyethyl, cyanomethyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, cyclohexyl,

phenyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, pyrazinyl, hydroxylmethyl, hydroxypropyl, benzyl, formyl, phenylcarbonyl, methoxymethyl, furylmethyloxy, aminocarbonyl, N-methylaminocarbonyl, N-dimethylaminocarbonyl, N,N-methylamino, N-ethylamino, N,N-dipropylamino, N-butylamino, N-methyl-N-ethylamino, aminomethyl, N,N-dimethylaminomethyl, N-methyl-N-ethylaminomethyl, benzyloxy, and phenyloxy.

Claim 17. (Currently amended) The composition of Claim 16 wherein the cyclooxygenase-2 **selective** inhibitor is selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

3-(3,4-difluorophenyl)-4-(4-methylsulfonylphenyl)-2-(5H)-furanone;

3-phenyl-4-(4-methylsulfonylphenyl)-2-(5H)-furanone;

4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;

4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-hydroxyethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

[2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide;

4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide; and

4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide.

Claim 18. (Previously presented) The composition of Claim **[[9]]** **10** wherein the leukocyte activation inhibitor is a cyclosporin compound.

Claim 19. (Previously presented) The composition of Claim 18 wherein the cyclosporin compound is cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl].

Claim 20. (Currently amended) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a 5-lipoxygenase **selective** inhibitor, a cyclosporin compound and a cyclooxygenase-2 **selective** inhibitor selected from ~~**Dupont Dup 697, Taisho NS-398, meloxicam, flosulide**~~ **5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-thiophene, N-[2-cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide, 1,1-dioxide-4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide, N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]-methanesulfonamide** and compounds of Formula I or a pharmaceutically acceptable salt of a compound having Formula I:



(I)

wherein A is a 5-or 6-member ring substituent selected from partially unsaturated or unsaturated heterocyclo and carbocyclic rings;

wherein R^1 is at least one substituent selected from heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R^1 is optionally substituted at a substitutable position with

one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R^2 is selected from alkyl, and amino; and

wherein R^3 is a radical selected from halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclooxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, arylaminocarbonyl, alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, arylamino, N-aralkylamino, N-alkyl-N-arylaminocarbonyl, alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, N-aralkylaminoalkyl, alkyl-N-aralkylaminoalkyl, alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, arylsulfonyl, **and** alkyl-N-arylaminosulfonyl.

Claim 21. (Cancelled)

Claim 22. (Currently amended) A composition comprising:

a 5-lipoxygenase **selective** inhibitor selected from the group consisting of: (Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide, (1-Benzo[b]thien-2-yl-ethyl)-N-hydroxyurea, 4-[2',4'-difluorbiphenyl]-4-oxo-methyl-butanic acid, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridinyl)-2-propenamide, 1-methyl-6-[[[3-(tetrahydro-4-methoxy-2-methyl-2H-pyran-4-yl)-2-propenyl]oxy]methyl]-2(1H)-quinolinone, Hydroxy-N-[4-[3-(4-fluorophenoxy)phenyl]-3-butyn-2-yl]-urea, N-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N-hydroxyurea, [3-[5-(4-

fluorophenoxy)-2-furanyl]-1-methyl-2-propynyl]-N-hydroxyurea, (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea, [2-[[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-1,2,3,4-tetrahydro-1-oxo-6-isoquinolinyl]oxy]ethyl]-N-hydroxy-urea, dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one, 4-(2-quinolylmethoxy)-N-(3-fluorobenzyl-phenyl-amino-methyl-4-benzoic-acid, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]-butanoic acid, [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid, 1-([5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]aminoethyl)-4-diphenylmethoxypiperidine, 2-[2,3-dihydro-1-methoxy-6-(2-naphthalenylmethoxy)-1H-inden-1-yl]-thiazole, (6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxymethyl]-1-ethyl-2-quinolone, and 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone;

a cyclooxygenase-2 **selective** inhibitor selected from the group consisting of:

3-(3,4-difluorophenyl)-4-(4-methylsulfonylphenyl)-2-(5H)-furanone;

3-phenyl-4-(4-methylsulfonylphenyl)-2-(5H)-furanone;

4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;

4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-hydroxyethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

[2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide;

4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide; and

4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide; and

a cyclosporin compound.

Claim 23. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 3-(3,4-difluorophenyl)-4-(4-methylsulfonylphenyl)-2-(5H)-furanone.

Claim 24. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 3-phenyl-4-(4-methylsulfonylphenyl)-2-(5H)-furanone.

Claim 25. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

Claim 26. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

Claim 27. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

Claim 28. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine.

Claim 29. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine.

Claim 30. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide.

Claim 31. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide.

Claim 32. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[5-hydroxyethyl-3-phenylisoxazol-4-yl]benzenesulfonamide.

Claim 33. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is [2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide.

Claim 34. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide.

Claim 35. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 **selective** inhibitor is 4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide.

Claim 36. (Previously presented) A composition comprising 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, N'-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N'-hydroxyurea and a cyclosporin compound.

Claim 37. (Previously presented) A composition comprising 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, N'-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N'-hydroxyurea and a cyclosporin compound.

Claim 38. (Previously presented) A composition comprising 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, N'-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N'-hydroxyurea and a cyclosporin compound.